What is the prevalence of the HFE (Human Ferritin Gene) mutation in the population?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of HFE Gene Mutations in the Population

The C282Y mutation of the HFE gene has an allelic frequency of approximately 6.2% in populations of European ancestry, with homozygosity occurring in about 0.44-0.5% (1 in 200-260) of individuals of northern European descent. 1, 2

Geographic Distribution of HFE Mutations

  • The prevalence of C282Y mutation shows significant geographic variation across Europe, with a decreasing gradient from northwest to southeast 1
  • Highest frequencies are found in Ireland (12.5%) and lowest in Southern Europe (approaching 0%) 1
  • In the UK, approximately 1 in 147 blood donors were found to be homozygous for C282Y 3
  • The allelic frequency of C282Y in upper Northern Italy is about 3.2%, confirming the decreasing north-to-south gradient 4
  • On the island of Majorca (Spain), the C282Y mutation frequency was found to be 2.62% 5
  • In Greece, the C282Y allele frequency (2.3%) is lower than the European average (4%) but higher than the global average (1%) 6

Prevalence of Different HFE Genotypes

  • Homozygosity for C282Y (C282Y/C282Y) occurs in approximately 0.38-0.44% of European populations 1
  • The H63D mutation is more common, with an average allelic frequency of 14% in European populations 1
  • Compound heterozygosity (C282Y/H63D) occurs in approximately 1 in 42 individuals of European descent 3
  • Homozygosity for H63D occurs in approximately 1 in 42 individuals 3
  • The S65C mutation is less common with an allelic frequency of about 0.5%, with higher prevalence in certain regions like Brittany, France 1

Clinical Relevance of HFE Mutations

  • C282Y homozygosity is found in 80.6% of clinically recognized hemochromatosis patients of European ancestry 1
  • Compound heterozygosity (C282Y/H63D) accounts for only 3-5% of hemochromatosis cases 2, 7
  • Not all individuals with homozygous C282Y mutations develop clinical disease - penetrance is variable 2
  • In population screening studies, approximately 40-70% of C282Y homozygotes will develop clinical evidence of iron overload 7

Common Pitfalls in Understanding HFE Mutation Prevalence

  • Assuming uniform distribution of HFE mutations across all populations when there is significant geographic variation 1
  • Confusing allele frequency with genotype frequency (homozygosity is much less common than heterozygosity) 1
  • Assuming all individuals with the genetic predisposition will develop clinical hemochromatosis, when penetrance is incomplete 2
  • Failing to recognize that the frequency of C282Y homozygosity is significantly higher in clinically diagnosed hemochromatosis patients (80.6%) than in the general population (0.4%) 1, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HFE Gene Mutation and Hereditary Hemochromatosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevalence of HFE mutations in upper Northern Italy: study of 1132 unrelated blood donors.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.